Alexander L Luryi1, Michelle M Chen2, Saral Mehra1, Sanziana A Roman2, Julie A Sosa2,3,4, Benjamin L Judson5. 1. Department of Surgery, Yale University School of Medicine, New Haven, Connecticut. 2. Department of Surgery, Stanford University School of Medicine, Durham, North Carolina. 3. Duke Cancer Institute, Durham, North Carolina. 4. Duke Clinical Research Institute, Durham, North Carolina. 5. Department of Otolaryngology, Head and Neck Surgery, Yale University School of Medicine, New Haven, Connecticut.
Abstract
BACKGROUND: Oral cavity squamous cell cancer (SCC) is treated primarily with surgery. Rates of 30-day hospital readmission and mortality after surgery for oral cavity SCC are unknown. METHODS: We conducted a retrospective analysis of postoperative 30-day unplanned readmission and mortality in patients with oral cavity SCC in the National Cancer Data Base (NCDB). RESULTS: Among 21,681 cases, the 30-day unplanned readmission rate was 3.2%, and the 30-day mortality rate was 1.0%. Male sex (odds ratio [OR] = 1.23; p = .02), stage T3 (OR = 1.55; p = .007), or T4 (OR = 1.52; p = .002), and neck dissection (OR = 1.37; p = .04) were independently associated with readmission. Age 76 to 85 years (OR = 4.80; p < .001), age >85 years (OR = 10.24; p < .001), comorbidity index ≥1 (OR = 2.31; p < .001), and stage T3 (OR = 3.02; p < .001) or T4 (OR = 3.24; p < .001) were associated with 30-day mortality. CONCLUSION: Interventions aimed at decreasing hospital readmissions should target high-risk patients identified here. Factors associated with 30-day mortality reflect risk factors for overall mortality.
BACKGROUND: Oral cavity squamous cell cancer (SCC) is treated primarily with surgery. Rates of 30-day hospital readmission and mortality after surgery for oral cavity SCC are unknown. METHODS: We conducted a retrospective analysis of postoperative 30-day unplanned readmission and mortality in patients with oral cavity SCC in the National Cancer Data Base (NCDB). RESULTS: Among 21,681 cases, the 30-day unplanned readmission rate was 3.2%, and the 30-day mortality rate was 1.0%. Male sex (odds ratio [OR] = 1.23; p = .02), stage T3 (OR = 1.55; p = .007), or T4 (OR = 1.52; p = .002), and neck dissection (OR = 1.37; p = .04) were independently associated with readmission. Age 76 to 85 years (OR = 4.80; p < .001), age >85 years (OR = 10.24; p < .001), comorbidity index ≥1 (OR = 2.31; p < .001), and stage T3 (OR = 3.02; p < .001) or T4 (OR = 3.24; p < .001) were associated with 30-day mortality. CONCLUSION: Interventions aimed at decreasing hospital readmissions should target high-risk patients identified here. Factors associated with 30-day mortality reflect risk factors for overall mortality.
Authors: Hoda Badr; Maximiliano Sobrero; Joshua Chen; Tamar Kotz; Eric Genden; Andrew G Sikora; Brett Miles Journal: Oral Oncol Date: 2019-02-11 Impact factor: 5.337
Authors: Zachary G Schwam; Barbara Burtness; Wendell G Yarbrough; Saral Mehra; Zain Husain; Benjamin L Judson Journal: Cancer Med Date: 2015-10-16 Impact factor: 4.452
Authors: Carlos Miguel Chiesa-Estomba; Jon Alexander Sistiaga-Suárez; José Ángel González-García; Ekhiñe Larruscain Sarasola; Ariadna Valldeperes Vilanova; Xabier Altuna Journal: Int Arch Otorhinolaryngol Date: 2021-08-04
Authors: Marc Hamoir; Sandra Schmitz; Carlos Suarez; Primoz Strojan; Kate A Hutcheson; Juan P Rodrigo; William M Mendenhall; Ricard Simo; Nabil F Saba; Anil K D'Cruz; Missak Haigentz; Carol R Bradford; Eric M Genden; Alessandra Rinaldo; Alfio Ferlito Journal: Cancers (Basel) Date: 2018-08-10 Impact factor: 6.639
Authors: Iain L Hutchison; Fran Ridout; Sharon M Y Cheung; Allan Hackshaw; Neil Shah; Peter Hardee; Christian Surwald; Janavikulam Thiruchelvam; Leo Cheng; Tim K Mellor; Peter A Brennan; Andrew J Baldwin; Richard J Shaw; Wayne Halfpenny; Martin Danford; Simon Whitley; Graham Smith; Malcolm W Bailey; Bob Woodwards; Manu Patel; Joseph McManners; Chi-Hwa Chan; Andrew Burns; Prav Praveen; Andrew C Camilleri; Chris Avery; Graham Putnam; Keith Jones; Keith Webster; William P Smith; Colin Edge; Iain McVicar; Nick Grew; Stuart Hislop; Nicholas Kalavrezos; Ian C Martin Journal: Br J Cancer Date: 2019-10-15 Impact factor: 7.640